46 results about "Citrullination" patented technology

Antibodies against citrullinated protein antigens (ACPA) have shown their relevance for the diagnosis and possibly pathogenesis in arthritis. Described are means and methods for determining antibodies against homocitrulline-containing proteins or carbamylated proteins/peptides (anti-CarP) for the classification of individuals suffering from, or at risk of suffering from, arthritis.

The present invention relates to the field of biomarkers. More specifically, the present invention relates to biomarkers useful in diagnosing brain injury or neurodegeneration. In one embodiment, a method for diagnosing brain injury in a patient comprises the steps of (a) obtaining a sample from the patient; (b) determining the ratio of citrullinated to unmodified arginine residues at one or more arginine residues of one or more brain injury biomarker proteins; and (c) correlating the ratio to a patient having brain injury or to a patient not having brain injury, thereby providing the diagnosis.

The present invention is in the field of diagnostic methods. It provides a new marker antibody for rheumatoid arthritis as well as a new method for detecting rheumatoid arthritis. It also provides means and methods for predicting whether a subject will develop rheumatoid arthritis. The invention is based on the discovery that patients with rheumatoid arthritis have antibodies in their circulation that react specifically with citrullinated antibodies. In one aspect, the invention therefore relates to an antibody comprising a citrulline residue. In another aspect, the invention provides a method for the detection of antibodies specific for rheumatoid arthritis in a sample from a subject, wherein the sample is contacted with a citrullinated antibody and wherein it is determined whether the sample comprises antibodies specifically reactive with the citrullinated antibody.

The present invention provides natural occurring, recombinant and synthetic chemokines, interleukins and cytokines in which at least one arginine residue is replaced by or modified into a cltrulline residue. The present Invention also relates to the use of said chemokines, interleukins or cytokines and pharmaceutical compositions comprising said chemokines, interleukins or cytokines as anti-inflammatory agents and as haematopoietic cell (including stem-cell, progenitor cell and leukocyte) or endothelial cell mobilizing agents. Furthermore, the present invention relates to the use of said chemokines, interleukins or cytokines to create antibodies and to use said chemokines, interleukins, cytokines and/or said antibodies as diagnostic tools and as a medicine. In addition, the present invention provides for the processes for the identification and production of the citrullinated chemokines, interleukins or cytokines of the invention.

Autoantibodies reacting against citrullinated peptides derived from C-telopeptides of type I and type II collagens are found in patients with rheumatoid arthritis. They detect sequences —YYXA from α1 or —FYXA from α2 chain of type I collagen or —YMXA from α1 chain of type II collagen, where X is citrulline. The antibodies are different from anti-filaggrin antibodies. The peptides of the invention can be used in diagnosis of rheumatoid arthritis. Oral administration of citrullinated peptides can induce tolerance and lead to the treatment of rheumatoid arthritis.

The invention relates to a method of determining the inflammatory disorder status of a subject comprising detecting the presence or absence, or the level, of (i) citrullinated tenascin-C and/or one or more fragments of citrullinated tenascin-C; and/or (ii) autoantibodies with specificity for citrullinated tenascin-C and/or one or more fragments of citrullinated tenascin-C, in a sample from said subject.

Guanadinylated aminoglycoside-lipid conjugates are prepared. Such conjugates may comprise an aminoglycoside such as an aminoglyucoside antibiotic like neomycin or kanamycin, at least one guanidino group attached to a primary or secondary carbon atom of the aminoglyucoside group and at least one lipid group attached through a bond or a linker to a branched carbon atom of the aminoglycoside. These conjugates exhibit improve antibacterial activity and may be used in conjunction with another antibiotic.

The invention belongs to the field of gene engineering, and relates to a zipper fastener structure for promoting formation of protein dimers and an application thereof, and the zipper fastener can beused for dimerization of homologous proteins and dimerization of heterologous proteins, and can also be used for polypeptide cyclization, dimerization of polypeptides and extension of polypeptides. Some examples can obtain an ESAT6-CFP10 dimer close to native conformation, wherein the dimer has better solubility and has a better stimulation effect on memory T cells than ESAT6-CFP10 protein expressed by linear fusion. The inventor also finds that the dimer zipper fastener can help to form more stable cyclic polypeptide, and the CCP polypeptide added with the dimer fastener can increase the detection rate of citrullinated antibody in serum of rheumatoid arthritis patients.

The invention belongs to the technical field of medicine and biochemistry, and particularly relates to an anti-mutant citrulline waveform protein antibody detection kit. The kit comprises a first detection reagent and a second detection reagent. The first detection reagent comprises a buffer agent, a stabilizer, an electrolyte, a sensitizer, a surfactant and a preservative. The second detection reagent comprises latex microspheres coupled with protein antigens of citrullinated waveform protein and mutants thereof, a buffer agent, a protein protective agent, an electrolyte and a preservative. The anti-mutant citrulline waveform protein antibody detection kit adopts a latex enhanced turbidimetric immunoassay method for determination, and has the advantages of rapidness, sensitivity, good accuracy, high specificity and the like compared with the traditional anti-mutant citrulline waveform protein antibody detection kit.

Provided herein are methods and markers for diagnosing cardiovascular disease and/or neurodegenearative diseases in a subject. The methods include obtaining a biological sample from a subject in needof diagnosis and detecting the amount of a citrullinated protein or a citrullinated peptide in the biological sample obtained from said subject.

The invention discloses a compound which is shown as a formula 2-GBA, 2-GBA-1, 2-GBA-N3, 2-GBA-N3-1, 2-GBA-Biotin or 2-GBA-Biotin-1. The compound shown as 2-GBA can react with citrulline under a neutral condition, namely, the compound can remove protein of citrulline like an antibody. Azido and alkynyl substitution are carried out on a parent nucleus of the compound shown as 2-GBA, biotin and fluorescein are introduced through click reaction, and the prepared compound shown as 2-GBA-Biotin can be used for labeling and detecting citrullinated protein. The invention also discloses application ofthe compound.

Compositions and methods are provided for diagnosis and treatment of rheumatoid arthritis. Defects in T cell receptor signaling lower the activation threshold of RA T cells, thus predisposing for a failure in maintenance of immune tolerance. Overexpression of B-Raf and/or K-Ras in CD4 T cells lowers the threshold to respond to TCR triggering in the absence of costimulation and increases responses to citrullinated peptides and other autoantigens.

The present invention relates to a high-affinity anti-cyclic citrullinated peptide single-chain variable region tetravalent micro-molecule antibody. The invention proves that an anti-CCP antibody is not only a serologic marker for RA diagnosis, but also plays an important role in RA pathogenesis, and provides a test basis for RA targeted therapy with a citrullinated antigen as a target. In the present invention, a CCP epitope is used as a therapeutic target and an entry point. The research content involves multiple levels at which the CCP may be involved in the RA pathogenesis, so as to systematically and comprehensively reveal the role of the anti-CCP antibody in the RA pathogenesis. The peptide chain of an anti-CCP- ScFv antibody and a tetramer antibody with a P53 framework used in the invention are completely humanized sequences, acted on and targeted to an initiation of the RA pathogenesis and chronic process of inflammation, so as to have more pertinence. Different from existing downstream inflammatory response mediators and inflammatory signaling pathway mediators that antagonize the RA pathogenesis, the high-affinity anti-cyclic citrullinated peptide tetravalent micro-molecule antibody of the invention has more leading and accurate targetability of the target, and has better potential for transformation of technological achievements and prospect for biopharmaceutical development. In addition, an anti-CCP+RA and an anti-CCP-RA targeted by the high-affinity anti-cyclic citrullinated peptide tetravalent micro-molecule antibody of the invention may be two different disease subtypes of the RA, so that the antibody may become a new hope for accurately targeted therapy for such patients.

Compositions and methods for detection of anti-citrullinated protein antibodies (ACPAs) in rheumatoid arthritis (RA) patients. Patient samples known or suspected of containing ACPAs were probed against citrullinated proteins, and antibody responses to 190 citrullinated proteins in 20 RA patients were investigated. Unique antibody reactivity patterns in both clinical anti-cyclic citrullinated peptide assay positive (CCP+) and negative (CCP−) RA patients were observed. At individual antigen levels, six novel antibody/antigen complexes were discovered and validated against specific citrullinated antigens (Myelin Basic Protein (MBP), osteopontin (SPP1), flap endonuclease (FEN1), insulin like growth factor binding protein 6 (IGFBP6), insulin like growth factor I (IGF1) and stanniocalcin-2 (STC2)) in RA patients. Identification of immune-dominant epitope(s) for citrullinated MBP was also performed. The identified biomarkers have high specificity, especially MBP.

The present invention concerns a chimeric polypeptide, capable of detecting the antibodies generated in rheumatoid arthritis, comprising at least two citrulinated peptide subunits: (i) one derived from the α or β chain of the fibrin and (ii) a second derived from the filaggrin. In addition, the invention comprises an antigenic composition, a method and a kit for the diagnosis of rheumatoid arthritis, from the detection of the autoantibodies generated during the course of said disease.

The present invention refers to the use of citrullinated synthetic peptides for the diagnosis of rheumatoid arthritis (RA).

The invention is in the field of methods and preparations for medical treatments, in particular the treatment of idiopathic pulmonary fibrosis (IPF). The invention provides such methods wherein antibodies or fragments thereof that react with selected citrullinated epitopes are used in the treatment of IPF. Antibodies against citrullinated epitopes situated at the amino terminus of histone polypeptides H2A and H4 were found to be particularly useful. The invention therefore relates to an antibody specifically reactive with a citrullinated epitope on the N-terminus of deiminated histone H2A or H4 for use in the prevention or treatment of idiopathic pulmonary fibrosis.

The invention relates to a modified phage display that allows the specific detection of citrullinated proteins. More specifically, the invention relates to a method for citrullinating proteins displayed by phage, without losing phage infectivity, and the detection of those proteins by biopanning. In a preferred embodiment, the phage is a T7 phage.